Annual Report and Form 20-F Information

The report describes AstraZeneca's strong 2023 performance, including Total Revenue of $45,811 million and continued growth across its therapy areas. It also highlights formal sustainability governance, with the Sustainability Committee monitoring strategy execution and Bureau Veritas providing limited assurance. The company reports Scope 1, Scope 2 and all 15 Scope 3 categories, alongside 1,511,334 MWh of total energy consumption. Sustainability highlights include a 67.6% reduction in Scope 1 and 2 emissions from the 2015 baseline, expansion of AZ Forest to 200 million trees by 2030, and access-to-healthcare programmes reaching more than 66 million people cumulatively.